# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN-TD
- Date: 1991-05-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism. **S**

## Objective

TSH: 0.005 mIU/L (low); Free T4: 3.6 ng/dL (high); Total T3: 280 ng/dL (high); TSH receptor antibody: 8.2 [IU]/L (high); White cell count: 6.8 10*3/uL; Absolute neutrophil count: 3.9 10*3/uL; Hemoglobin: 14.8 g/dL; ALT: 32 U/L; Creatinine: 0.92 mg/dL; eGFR: 87 mL/min/1.73 m²; Potassium: 4.2 mmol/L. All results are synthetic.

BP 142/68 mmHg; pulse 88 bpm; respirations 16/min; temperature 37.1 °C; oxygen saturation 98% on room air; weight 86 kg; BMI 24.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation; Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Continued without change: Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) **S**
- Started: Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily **S**

## Plan

- Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery). Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
